Clinical Trial Details
— Status: Not yet recruiting
Administrative data
NCT number |
NCT06460363 |
Other study ID # |
KUH507T056 |
Secondary ID |
|
Status |
Not yet recruiting |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
September 1, 2024 |
Est. completion date |
December 31, 2028 |
Study information
Verified date |
June 2024 |
Source |
Kuopio University Hospital |
Contact |
Ville Ihalainen |
Phone |
+358 447176388 |
Email |
ville.ihalainen[@]pshyvinvointialue.fi |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
The goal of this clinical trial is to learn if transcranial alternating current stimulation
can shorten the duration of delirium in intensive care setting. The main question it aims to
answer:
- Is it possible to shorten the duration of delirium with transcranial alternating current
stimulation?
Researchers will compare experimental treatment to sham.
Participants will receive experimental or sham treatment on maximum of two days depending on
their delirium status. Duration of delirium is recorded and reported as "days alive and free
of delirium".
Description:
Delirium is an acute-onset brain dysfunction related to extensive surgery or critical illness
that leads to altered mental status and cognitive deficits. Delirium is associated with an
increased length of stay in the ICU, cost of care, excessive mortality, and long-term
cognitive and functional impairment. Although numerous prophylactic methods have been
proposed, currently, no pharmacological or non-pharmacological methods are clinically
effective. Patients with delirium have altered electroencephalography (EEG) findings among
which most important are general slowing of EEG frequencies and dysconnectivity. Faster EEG
frequencies, especially alpha-, beta-, and gamma-bands, are correlated with higher cognitive
functions, such as memory and orientation. Transcranial alternating current stimulation
(TACS) is a novel, noninvasive brain stimulation technology that cab modulate EEG frequencies
by entraining of endogenous brain oscillations in response to exogenous stimuli. TACS has
been shown to improve episodic memory, orientation, and cholinergic dysfunction in patients
with Alzheimer's disease. TACS also increases alpha and gamma frequencies in EEG, and an
increase in these frequencies is associated with the improvement of clinical symptoms. TACS
has been shown to target key components of delirium pathophysiology, such as slowing of EEG
frequencies and cholinergic dysfunction. Thus, we hypothesized that TACS could shorten the
duration of delirium and decrease cognitive decline. We aim to test this hypothesis in a
double-blind randomized trial and assess the effect of TACS on duration of delirium, EEG,
biomarkers and long-term cognition.